Stem Cell Clinic

Tenax Therapeutics Announces Reverse Stock Split

By Global News Feed

CHAPEL HILL, N.C., Dec. 29, 2023 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, announced today that it will be executing a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-80. The reverse stock split will become effective at 5:00 pm Eastern Time on January 2, 2024. The Company’s common stock will begin trading on the Nasdaq Capital Market on a split-adjusted basis beginning upon market open on January 3, 2024, under the Company’s existing trading symbol “TENX”.

Go here to read the rest:
Tenax Therapeutics Announces Reverse Stock Split

Altamira Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

By Global News Feed

HAMILTON, BERMUDA, Dec. 29, 2023 (GLOBE NEWSWIRE) -- HAMILTON, BERMUDA, Dec. 29, 2023 -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company providing nanoparticle-based technology for efficient RNA delivery to extrahepatic targets, announced that it received a notification letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") on December 28, 2023, indicating that the Company has regained compliance with the minimum bid price requirement. As a result, the listing matter has been closed.

See the original post:
Altamira Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Kane Biotech Announces Correction to Press Release

By Global News Feed

WINNIPEG, Manitoba, Dec. 29, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company”, “Kane” or “Kane Biotech”) today announces a correction to its press release dated December 28, 2023. The maturity date of the Company’s amended and restated credit facility between Pivot I Financial Limited Partnership and the Company dated August 31, 2021, as amended, has been extended to March 31, 2024, not March 31, 2023 as stated in the release.

See original here:
Kane Biotech Announces Correction to Press Release

Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

By Global News Feed

BOSTON, Dec. 29, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers, reported today that Pyxis Oncology’s Compensation Committee of the Board of Directors approved a stock option grant to Ken Kobayashi, M.D., the Company’s newly appointed Chief Medical Officer, in connection with his employment with the Company effective on November 27, 2023. The equity award was granted under the Pyxis Oncology, Inc. 2022 Inducement Plan with a grant date of December 29, 2023, as an inducement material to Dr. Kobayashi entering into employment with Pyxis Oncology, in accordance with Nasdaq Listing Rule 5635(c)(4).

The rest is here:
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Valneva Provides Updated 2023 Financial Guidance

By Global News Feed

Saint-Herblain (France), December 29, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the Company is modifying its financial guidance for 2023. Product sales guidance remains unchanged, as do anticipated R&D expenses. The €90 million to €110 million of other income related to proceeds from potential sale of the Company’s priority review voucher (PRV), which was previously expected before year-end, is now expected in early 2024.

Read more:
Valneva Provides Updated 2023 Financial Guidance

Roche enters into a definitive agreement to acquire LumiraDx’s Point of Care technology combining multiple diagnostic modalities on a single platform

By Global News Feed

Basel, 29 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the entry into a definitive agreement to acquire select parts of the LumiraDx group (NASDAQ GS: LMDX) related to LumiraDx’s innovative Point of Care technology. Following closing of the transaction, which is expected by mid-2024, the acquired entities will be fully integrated into Roche Diagnostics.

See the original post:
Roche enters into a definitive agreement to acquire LumiraDx's Point of Care technology combining multiple diagnostic modalities on a single platform

Blueberries Medical Announces Closing of C$2 Million Non-Brokered Private Placement

By Global News Feed

TORONTO, Dec. 29, 2023 (GLOBE NEWSWIRE) -- Blueberries Medical Corp. (CSE: BBM) (OTC: BBRRF) (FRA: 1OA) (the “Company” or "Blueberries"), a Latin American licensed producer of medicinal cannabis and cannabis-derived products, announces a non-brokered private placement consisting of the sale of 180,716,00 common shares (“Common Shares”) at a price of C$0.011 per Common Share for aggregate gross proceeds of approximately C$1,987,876 (or approximately US$1,250,000) (the “Offering”). The net proceeds from the sale of the Common Shares will be used to repay existing debt and for general corporate and working capital purposes.

Read the original here:
Blueberries Medical Announces Closing of C$2 Million Non-Brokered Private Placement

→←